Hunan Dajiaweikang Pharmaceutical Industry Co Ltd. Stock Analysis 301126.SZ

Hunan Dajiaweikang Pharmaceutical Industry Co., Ltd. engages in the distribution and sales of drugs, biological products, medical devices, and other products. The company is headquartered in Changsha, Hunan and currently employs 5,339 full-time employees. The company went IPO on 2021-12-07. The firm mainly operates in four businesses. The distribution business includes direct sales and allocation models, primarily dealing in new and special drugs such as anti-tumor drugs, immunomodulatory drugs, cardiovascular drugs, respiratory drugs, and antiviral drugs. The retail business mainly operates direct-to-patient (DTP) pharmacies and Special Service pharmacies. The pharmaceutical manufacturing business is primarily engaged in the research and development of original chemical drugs, innovative traditional Chinese medicines, first-to-market generic drugs, and health products. The medical service business is primarily engaged in reproductive hospital-related businesses. The firm mainly conducts its businesses within domestic market.